Benign prostatic hyperplasia (BPH) is a condition occurring in men when the prostate gland is enlarged. Benign prostatic hyperplasia is also termed as benign prostatic hypertrophy or benign prostatic obstruction. Prostate gland grows in primarily two phases, firstly during puberty when the size of the prostate doubles and the second growth phase starts at 25 years and continues throughout the lifetime. While the prostate gland enlarges in a man, it presses and pinches the urethra making the bladder wall thick. This pressure and squeeze on the urethra weaken the bladder and makes it lose the ability to empty the urine completely. Urinary retention and narrowing of the urethra can cause many problems which are associated with benign prostatic hyperplasia. Benign prostatic hyperplasia is one of the common prostate problems for men older than age 50.
Highlights
The global Benign Prostatic Hyperplasia Testing market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Benign prostatic hyperplasia testing market is primarily driven by a few key factors such as the growing geriatric male population, patient awareness regarding rising healthcare concerns, increase in healthcare expenditure, increasing government initiatives and availability of minimally invasive surgery as a drug replacement, faster and easy performing diagnosis test results. The market is likely to grow owing to the novel diagnostic methods which are accurate than the conventional PSA blood test for benign prostatic hyperplasia which is effective in diagnosis and is expected to fuel the growth of benign prostatic hyperplasia testing market.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Benign Prostatic Hyperplasia Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Benign Prostatic Hyperplasia Testing.
The Benign Prostatic Hyperplasia Testing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Benign Prostatic Hyperplasia Testing market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Benign Prostatic Hyperplasia Testing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
AEternaZentaris
Astellas Pharma
Eli Lilly and Company
IntelGenx Technologies Corp
Nymox Pharmaceutical Corporation
Protox Therapeutics
Quest PharmaTech
Segment by Type
Urinalysis
Prostate-Specific Antigen (PSA) Blood Test
Urodynamic Test
Cystoscopy
Segment by Application
Hospitals
Diagnostic Centers
Clinics
Research Institutes
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Benign Prostatic Hyperplasia Testing companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Benign Prostatic Hyperplasia Testing 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Urinalysis
1.2.3 Prostate-Specific Antigen (PSA) Blood Test
1.2.4 Urodynamic Test
1.2.5 Cystoscopy
1.3 麻豆原创 by Application
1.3.1 Global Benign Prostatic Hyperplasia Testing 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Diagnostic Centers
1.3.4 Clinics
1.3.5 Research Institutes
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Benign Prostatic Hyperplasia Testing 麻豆原创 Perspective (2018-2029)
2.2 Benign Prostatic Hyperplasia Testing Growth Trends by Region
2.2.1 Global Benign Prostatic Hyperplasia Testing 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Benign Prostatic Hyperplasia Testing Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Benign Prostatic Hyperplasia Testing Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Benign Prostatic Hyperplasia Testing 麻豆原创 Dynamics
2.3.1 Benign Prostatic Hyperplasia Testing Industry Trends
2.3.2 Benign Prostatic Hyperplasia Testing 麻豆原创 Drivers
2.3.3 Benign Prostatic Hyperplasia Testing 麻豆原创 Challenges
2.3.4 Benign Prostatic Hyperplasia Testing 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Benign Prostatic Hyperplasia Testing Players by Revenue
3.1.1 Global Top Benign Prostatic Hyperplasia Testing Players by Revenue (2018-2023)
3.1.2 Global Benign Prostatic Hyperplasia Testing Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Benign Prostatic Hyperplasia Testing 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Benign Prostatic Hyperplasia Testing Revenue
3.4 Global Benign Prostatic Hyperplasia Testing 麻豆原创 Concentration Ratio
3.4.1 Global Benign Prostatic Hyperplasia Testing 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Benign Prostatic Hyperplasia Testing Revenue in 2022
3.5 Benign Prostatic Hyperplasia Testing Key Players Head office and Area Served
3.6 Key Players Benign Prostatic Hyperplasia Testing Product Solution and Service
3.7 Date of Enter into Benign Prostatic Hyperplasia Testing 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Benign Prostatic Hyperplasia Testing Breakdown Data by Type
4.1 Global Benign Prostatic Hyperplasia Testing Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Benign Prostatic Hyperplasia Testing Forecasted 麻豆原创 Size by Type (2024-2029)
5 Benign Prostatic Hyperplasia Testing Breakdown Data by Application
5.1 Global Benign Prostatic Hyperplasia Testing Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Benign Prostatic Hyperplasia Testing Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Benign Prostatic Hyperplasia Testing 麻豆原创 Size (2018-2029)
6.2 North America Benign Prostatic Hyperplasia Testing 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Benign Prostatic Hyperplasia Testing 麻豆原创 Size by Country (2018-2023)
6.4 North America Benign Prostatic Hyperplasia Testing 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Benign Prostatic Hyperplasia Testing 麻豆原创 Size (2018-2029)
7.2 Europe Benign Prostatic Hyperplasia Testing 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Benign Prostatic Hyperplasia Testing 麻豆原创 Size by Country (2018-2023)
7.4 Europe Benign Prostatic Hyperplasia Testing 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Benign Prostatic Hyperplasia Testing 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Benign Prostatic Hyperplasia Testing 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Benign Prostatic Hyperplasia Testing 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Benign Prostatic Hyperplasia Testing 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Benign Prostatic Hyperplasia Testing 麻豆原创 Size (2018-2029)
9.2 Latin America Benign Prostatic Hyperplasia Testing 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Benign Prostatic Hyperplasia Testing 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Benign Prostatic Hyperplasia Testing 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Benign Prostatic Hyperplasia Testing 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Benign Prostatic Hyperplasia Testing 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Benign Prostatic Hyperplasia Testing 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Benign Prostatic Hyperplasia Testing 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AEternaZentaris
11.1.1 AEternaZentaris Company Detail
11.1.2 AEternaZentaris Business Overview
11.1.3 AEternaZentaris Benign Prostatic Hyperplasia Testing Introduction
11.1.4 AEternaZentaris Revenue in Benign Prostatic Hyperplasia Testing Business (2018-2023)
11.1.5 AEternaZentaris Recent Development
11.2 Astellas Pharma
11.2.1 Astellas Pharma Company Detail
11.2.2 Astellas Pharma Business Overview
11.2.3 Astellas Pharma Benign Prostatic Hyperplasia Testing Introduction
11.2.4 Astellas Pharma Revenue in Benign Prostatic Hyperplasia Testing Business (2018-2023)
11.2.5 Astellas Pharma Recent Development
11.3 Eli Lilly and Company
11.3.1 Eli Lilly and Company Company Detail
11.3.2 Eli Lilly and Company Business Overview
11.3.3 Eli Lilly and Company Benign Prostatic Hyperplasia Testing Introduction
11.3.4 Eli Lilly and Company Revenue in Benign Prostatic Hyperplasia Testing Business (2018-2023)
11.3.5 Eli Lilly and Company Recent Development
11.4 IntelGenx Technologies Corp
11.4.1 IntelGenx Technologies Corp Company Detail
11.4.2 IntelGenx Technologies Corp Business Overview
11.4.3 IntelGenx Technologies Corp Benign Prostatic Hyperplasia Testing Introduction
11.4.4 IntelGenx Technologies Corp Revenue in Benign Prostatic Hyperplasia Testing Business (2018-2023)
11.4.5 IntelGenx Technologies Corp Recent Development
11.5 Nymox Pharmaceutical Corporation
11.5.1 Nymox Pharmaceutical Corporation Company Detail
11.5.2 Nymox Pharmaceutical Corporation Business Overview
11.5.3 Nymox Pharmaceutical Corporation Benign Prostatic Hyperplasia Testing Introduction
11.5.4 Nymox Pharmaceutical Corporation Revenue in Benign Prostatic Hyperplasia Testing Business (2018-2023)
11.5.5 Nymox Pharmaceutical Corporation Recent Development
11.6 Protox Therapeutics
11.6.1 Protox Therapeutics Company Detail
11.6.2 Protox Therapeutics Business Overview
11.6.3 Protox Therapeutics Benign Prostatic Hyperplasia Testing Introduction
11.6.4 Protox Therapeutics Revenue in Benign Prostatic Hyperplasia Testing Business (2018-2023)
11.6.5 Protox Therapeutics Recent Development
11.7 Quest PharmaTech
11.7.1 Quest PharmaTech Company Detail
11.7.2 Quest PharmaTech Business Overview
11.7.3 Quest PharmaTech Benign Prostatic Hyperplasia Testing Introduction
11.7.4 Quest PharmaTech Revenue in Benign Prostatic Hyperplasia Testing Business (2018-2023)
11.7.5 Quest PharmaTech Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
AEternaZentaris
Astellas Pharma
Eli Lilly and Company
IntelGenx Technologies Corp
Nymox Pharmaceutical Corporation
Protox Therapeutics
Quest PharmaTech
听
听
*If Applicable.
